LAS VEGAS — In this Healio Video Perspective from Clinical Trials at the Summit, Christine Kay, MD, discusses phase 1/2 results for OPGx-LCA5, a gene therapy for Leber congenital amaurosis.
She presented 12-month results of three participants who received a low-dose subretinal injection of OPGx-LCA5 (Opus Genetics). The average visual acuity improvement was 3.5 lines of vision, according to Kay, with all three patients experiencing vision improvements as demonstrated by a multi-luminance mobility test.
{{VIDEO}}
Two patients showed a statistically significant improvement in object